Skip to main content

Table 6 Drug-likeness properties of the newly designed compounds

From: Structure-based design of some quinazoline derivatives as epidermal growth factor receptor inhibitors

Molecule MW TPSA WLOGP No. of H-bond donors No of H-bond acceptors RO5 violations
Molecule 1 591.63 106.63 7.2 3 7 2
Molecule 2 674.55 106.63 8.36 3 7 2
Molecule 3 591.63 106.63 7.2 3 7 2
Molecule 4 626.08 106.63 7.86 3 7 2
Molecule 5 609.62 106.63 7.76 3 8 2
Molecule 6 626.08 106.63 7.86 3 7 2
Molecule 7 609.62 106.63 7.76 3 8 2
Molecule 8 674.55 106.63 8.36 3 7 2
Molecule 9 658.09 106.63 8.51 3 8 2
Molecule 10 641.64 106.63 8.66 3 9 2
Molecule 11 621.66 115.86 7.21 3 8 2
Molecule 12 621.66 115.86 7.21 3 8 2
Molecule 13 644.07 106.63 8.42 3 8 2
Molecule 14 644.07 106.63 8.42 3 8 2
Molecule 15 639.65 115.86 7.77 3 9 2
Molecule 16 656.1 115.86 7.87 3 8 2